Mode of progression in smoldering multiple myeloma: a study of 406 patients.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
17 Jan 2024
17 Jan 2024
Historique:
received:
23
09
2023
accepted:
05
01
2024
revised:
28
12
2023
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
16
1
2024
Statut:
epublish
Résumé
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification. Median follow-up was 3.9 years. Among high-risk patients who did not receive treatment in the SMM phase (n = 71), 51 progressed by last follow-up; the MDEs included: bone lesions (37%), anemia (35%), hypercalcemia (8%), and renal failure (6%); 24% met MM criteria based on marrow plasmacytosis (≥60%) and/or free light chain ratio (>100); 45% had clinically significant MDEs (hypercalcemia, renal insufficiency, and/or bone lesions). MM diagnosis was made based on surveillance labs/imaging(45%), testing obtained due to provider suspicion for progression (14%), bone pain (20%), and hospitalization/ED presentations due to MM complications/symptoms (4%). The presentation was undocumented in 14%. A high proportion (45%) of patients with high-risk SMM on active surveillance develop end-organ damage at progression. About a quarter of patients who progress to MM are not diagnosed based on routine interval surveillance testing.
Identifiants
pubmed: 38228628
doi: 10.1038/s41408-024-00980-5
pii: 10.1038/s41408-024-00980-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Informations de copyright
© 2024. The Author(s).
Références
Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302:1347–9.
doi: 10.1056/NEJM198006123022405
pubmed: 7374679
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
doi: 10.1016/S1470-2045(14)70442-5
pubmed: 25439696
Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6:e486.
doi: 10.1038/bcj.2016.100
pubmed: 27768092
pmcid: 5098258
Thorsteinsdóttir S, Gíslason GK, Aspelund T, Rögnvaldsson S, Óskarsson JÞ, Sigurðardóttir GÁ, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29:467–72.
doi: 10.1038/s41591-022-02183-6
pubmed: 36747117
Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586–92.
doi: 10.1182/blood-2007-05-088443
pubmed: 17576818
Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59.
doi: 10.1038/s41408-018-0077-4
pubmed: 29895887
pmcid: 5997745
Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102.
doi: 10.1038/s41408-020-00366-3
pubmed: 33067414
pmcid: 7567803
Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126–37.
doi: 10.1200/JCO.19.01740
pubmed: 31652094
Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369:438–47.
doi: 10.1056/NEJMoa1300439
pubmed: 23902483
Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020;34:1840–52.
doi: 10.1038/s41375-020-0718-z
pubmed: 32024950
pmcid: 7326703
Mateos M-V, Martinez-Lopez J, Rodriguez Otero P, Gonzalez-Calle V, Gonzalez MS, Oriol A, et al. Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Blood. 2019;134:781.
doi: 10.1182/blood-2019-125204
Kazandjian D, Hill E, Morrison C, Dew A, Korde N, Mailankody S, et al. Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (-R): a phase 2 clinical and correlative study. Blood. 2020;136:43–5.
doi: 10.1182/blood-2020-136148
Liu C-j, Ghobrial IM, Bustoros M, Reyes K, Hornburg K, Badros AZ, et al. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma. Blood. 2018;132:154.
doi: 10.1182/blood-2018-154
Manasanch EE, Jagannath S, Lee HC, Patel KK, Graham C, Kaufman GP, et al. A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM). Blood. 2019;134:3116.
doi: 10.1182/blood-2019-123205
Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127–36.
doi: 10.1016/S1470-2045(16)30124-3
pubmed: 27402145
Mateos MV, Hernández MT, Salvador C, Rubia J, de Arriba F, López-Corral L, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study. Eur J Cancer. 2022;174:243–50.
doi: 10.1016/j.ejca.2022.07.030
pubmed: 36067617
Rajkumar SV, Kumar S, Lonial S, Mateos MV. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 2022;12:129.
doi: 10.1038/s41408-022-00719-0
pubmed: 36064707
pmcid: 9445066
Gertz MA, Vaxman I. Should high risk smoldering myeloma be treated outside a clinical trial: NO. Leuk Lymphoma. 2021;62:2565–7.
doi: 10.1080/10428194.2021.1951723
pubmed: 34261405
Hill E, Dew A, Kazandjian D. State of the science in smoldering myeloma: Should we be treating in the clinic? Semin Oncol. 2019;46:112–20.
doi: 10.1053/j.seminoncol.2019.03.001
pubmed: 31072611
Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828–38.
doi: 10.1182/blood.2021011670
pubmed: 35576526
pmcid: 9412010
Rajkumar SV, Landgren O, Mateos M-V. Smoldering multiple myeloma. Blood. 2015;125:3069–75.
doi: 10.1182/blood-2014-09-568899
pubmed: 25838344
pmcid: 4432003